Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07153172 | Safety Follow-up Study of Participants Dosed With INV-347 in Study INV-CL-108 | PHASE1 | RECRUITING | 91 | — | — | Aug 6, 2025 | Sep 15, 2027 | Mar 6, 2026 | 1 | Canada |
Number of events
| Arm | Type | Description |
|---|---|---|
| Participants from the study INV-CL-108 | EXPERIMENTAL | Participants who were dosed with INV-347 in the First In Human study INV-CL-108 and still have measurable plasma exposure of INV-347 are included to assess long term safety. |
| Name | Type | Description |
|---|---|---|
| INV-347 | DRUG | Participants who were dosed with INV-347 in the First In Human study INV-CL-108 and still have measurable plasma exposure of INV-347 are included to assess long term safety. |
Inclusion Criteria: 1. Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study. 2. Male or female (sex at birth). 3. Age 18 years or above at the...